TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03800017

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Hyperoxia
Description: Participants breathe 60% oxygen during exercise

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hyperoxia
Description: Participants breathe 60% oxygen during exercise
Study: NCT06218056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol (CBD) 800 mg
Description: CBD (400 mg) will be administered orally twice daily in the morning and again in the evening in 4 capsules each containing 100 mg of the active ingredient in the Ananda investigational new drug, ATL5. ATL5 is cannabidiol (CBD), extracted from hemp, at a 10% strength (softgel capsules with 100 mg/ml of CBD per capsule). The novel formulation is based on the principle that a water-free mixture of some concentrated inactive ingredients (excipients) self-assemble spontaneously into liquid nanodomains that contain the active component CBD. ATL5 Softgel Capsules will be manufactured by Baxco Pharmaceutical Inc., (California, USA) under cGMP conditions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo softgel capsule formulation will have a composition with the same relative proportions as the CBD ATL5 Softgel Capsules. This formulation will be manufactured by Baxco Pharmaceutical Inc under cGMP conditions. 4 softgel capsules of placebo will be administered to match the capsule number of the active compound, daily in the morning and evening for each of 56 days.
Study: NCT05775523

Intervention type: DRUG
Intervention: No intervention
Description: No intervention
Study: NCT04900701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy status
Description: Varying conditions of energy intake, thereby manipulating whether participants are in a state of energy restriction, balance, or surplus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy status
Description: Varying conditions of energy intake, thereby manipulating whether participants are in a state of energy restriction, balance, or surplus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy status
Description: Varying conditions of energy intake, thereby manipulating whether participants are in a state of energy restriction, balance, or surplus.
Study: NCT06512935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increase in the PEEP followed by decrease in the PEEP
Description: Changes in the ventilator PEEP and its effect on lung and cardiac hemodynamics

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decrease in the PEEP followed by increase in the PEEP
Description: Changes in the ventilator PEEP and its effect on lung and cardiac hemodynamics
Study: NCT06257394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib(Sprycel) arm
Description: ▪ Arm A : Philadelphia chromosome-positive : Induction (Except Consolidation #3 using Blinatumomab, all administration should be given with Dasatinib.)~* Morphologic CR after the Induction : Consolidation #1 → Consolidation #2 → Consolidation #3~  1. If MRD \& qPCR not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine → DI #1 → IM #2 → DI #2 → Maintenance~ 2. If MRD or qPCR positive after the post-consolidation #1 : Consolidation #3 using Blinatumomab →Allogeneic HSCT~* M2 or M3 after the Induction : Re-induction → Consolidation #2 → Consolidation #3 → Allogeneic HSCT~  1. If MRD \& qPCR not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine~ 2. If MRD or qPCR positive after the post-reinduction : Consolidation #3 using Blinatumomab~     * In Arm A, except Consolidation #3 using Blinatumomab, all administration should be given with Dasatinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-Dasatinib(Sprycel) arm
Description: ▪ Arm B : Other VHR ALL except Philadelphia chromosome-positive : Induction~* Morphologic CR after the Induction : Consolidation #1 → Consolidation #2 → Consolidation #3~  1. If MRD not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine → Allogeneic HSCT~ 2. If MRD positive after the post-consolidation #1 : Consolidation #3 using Blinatumomab →Allogeneic HSCT~* M2 or M3 after the Induction : Re-induction → Consolidation #2 → Consolidation #3‡ → Allogeneic HSCT~  1. If MRD not detected after the post-consolidation #1 : Consolidation #3 using HD MTX, HD Cytarabine~ 2. If MRD positive after the post-reinduction : Consolidation #3 using Blinatumomab
Study: NCT05454670

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-flap palatoplasty
Description: Two-flap palatoplasty used to correct cleft palate defect. The cleft palate is closed by separation of the nasal and the oral mucosa layers. Then approximation of the nasal mucosa layer, muscle layer is secured in the posterior palate and then the oral mucosa layer is secured

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two-flap palatoplasty
Description: Two-flap palatoplasty used to correct cleft palate defect. The cleft palate is closed by separation of the nasal and the oral mucosa layers. Then approximation of the nasal mucosa layer, muscle layer is secured in the posterior palate and then the oral mucosa layer is secured
Study: NCT05124769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Allowing Program (PAllow)
Description: Performing exercises considered to have a considerable supraspinatus/ infraspinatus tendon/muscle load (EMG muscle activity of \> 40% MVC).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Avoiding Program (PAvoid)
Description: Performing exercises selected to have a minimal insupraspinatus/ infraspinatus tendon/muscle load (EMG muscle activity of \<20% MVC).~These unloading exercises are performed for 6 weeks. In the second part of the exercise protocol, the loading exercises are applied, however without pain.~In case the patient still feels pain during the exercises in that period, the unloading exercises are continued.
Study: NCT05456503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPI-2620
Description: Radiotracer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPI-2620
Description: Radiotracer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPI-2620
Description: Radiotracer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPI-2620
Description: Radiotracer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPI-2620
Description: Radiotracer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPI-2620
Description: Radiotracer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPI-2620
Description: Radiotracer
Study: NCT06643598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abecedarian Approach
Description: The Abecedarian Approach is an early childhood behavioral education program that aims to improve the learning and cognitive development of children in high-risk or at-risk communities. This study will test the efficacy of implementing this approach in a virtual format.
Study: NCT05856266

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US)
Description: Ultrasound examination

Intervention type: OTHER
Group type: OTHER
Intervention: Haemophilia Joint Health Score (HJHS)
Description: Functional joint examination
Study: NCT05858125

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Media Navigation Aid Kit
Description: The Social media Navigation Aid Kit (SNAK) was created by using search terms, urinary incontinence, urinary leakage, and urogynecology, and querying various websites/blogs, Facebook, Instagram, and YouTube. These social media platforms were chosen based on the top three social media platforms used in Americans aged 50 to \>65 years old according to Pew Research Analytics (Pew paper). The experienced reviewer evaluated each platform for users that provided relevant, accurate, and specific content. The department of Urogynecology at UNM independently reviewed the curated pages and users for approval. Once approved, the various users and pages were then collected and a flyer was created. The flyer will be available via hardcopy, email, or text per patient preference.
Study: NCT05778903

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nerve block
Description: Suprazygomatic maxillary nerve block

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nerve block
Description: Suprazygomatic maxillary nerve block
Study: NCT06223087

Intervention type: OTHER
Intervention: winter swimming
Description: Intervention involves bathing/swimming in cold water during the winter months in open waters
Study: NCT04484259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Description: Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor plus aspirin
Description: Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel with aspirin
Description: Eligible patients will enter a 7-10 day run-in phase with aspirin 81 mg/ qd plus ticagrelor 90 mg bid after which they will discontinue aspirin and maintain ticagrelor 90 mg bid monotherapy for 10±3 days. After this period, patients will be randomized using a randomly generated computer sequence in a 1:1:1 fashion to either: a) ticagrelor 60 mg bid monotherapy; b) aspirin 81 mg qd plus ticagrelor 60 mg bid; c) aspirin 81 mg qd plus clopidogrel 75 mg qd. Randomized treatment will be maintained for 10±3 days.
Study: NCT05092373

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields Therapy
Description: Receive TTF

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields Therapy
Description: Receive TTF
Study: NCT06585033

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Spinal cord stimulation
Description: Stimulation off

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal cord stimulation
Description: Stimulation on
Study: NCT04939194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fast Track Protocol
Description: We will apply 22 items of ERAS society
Study: NCT04234659

Intervention type: DEVICE
Intervention: Clinical placement of a temporary IMPELLA® mechanical circulatory support device.
Description: Surgical placement of the IMPELLA® device for life threatening cardiogenic shock not responsive to other medical treatment.
Study: NCT06252220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DA-1726
Description: Active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DA-1726
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to DA-1726
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to DA-1726
Description: Placebo
Study: NCT04314895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
Description: NanoPac is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate paclitaxel nanoparticles within a well-characterized particle-size distribution. Following PCA, NanoPac is filled into a clear 60mL Type 1, USP, clear-glass vial (306 mg/vial) as a powder fill of nanoparticulate paclitaxel, closed with a bromobutyl rubber stopper and aluminum crimp seal, and sterilized by gamma irradiation. Prior to administration at the hospital/clinic, NanoPac will be reconstituted with 1% Polysorbate 80, NF in 0.9% Sodium Chloride for Injection, USP, to form a suspension. The suspension will be further diluted with 0.9% Sodium Chloride for Injection, USP to achieve the final clinical formulation.
Study: NCT05068063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal Saline
Description: Ultrasound-guided Femoral Triangle block with 20 mL of Bupivacaine 0.25% and IPACK block with 20 mL of normal saline 0.9%
Study: NCT05734521

Intervention type: BIOLOGICAL
Intervention: avalglucosidase alfa-NGPT (GZ402666) IV
Description: intravenous infusion

Intervention type: BIOLOGICAL
Intervention: avalglucosidase alfa-NGPT (GZ402666)
Description: exposed via pregnancy and lactation
Study: NCT04560179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation 78mg dose
Description: Inhaled tobramycin - 78mg administered every 12 hours for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation 150mg dose
Description: Inhaled tobramycin - 150mg administered every 12 hours for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation 216mg dose
Description: Inhaled tobramycin - 216mg administered every 12 hours for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation 300mg dose
Description: Inhaled tobramycin - 300mg administered every 12 hours for 14 days.
Study: NCT05169632

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Gaming Rehabilitation Program 1
Description: Brain training games with physical exercise component.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerized Gaming Rehabilitation Program 2
Description: Cognitive training games with physical exercise component.
Study: NCT06501716

Intervention type: PROCEDURE
Intervention: Indocyanine Green
Description: Tumor resection, direct visualization of the chiasm and both optic nerves and ICG administration will be provided as it is recommended by the standard of care. ICG will be administered by an injection of 5 mg of ICG diluted in a 10 mL syringe performed in the line closest to the heart followed by a 10-mL saline bolus. Using near-infrared lighting, the investigators will determine the time between anterior cerebral arteries (ACA) peak luminescence to the peak luminescence of the superior hypophyseal arteries enveloping the optic chiasm (ACA to chiasm time). Because luminescence of large vessels precedes small arterial penetration, signal from the ACAs was considered as time 0 to account for possible differences in the arm-brain time between patients. In addition, the investigators will analyze the proportion of superior hypophyseal branches on the chiasm that luminesced from ICG.
Study: NCT06048263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interpersonal psychotherapy (IPT)
Description: The ROSE intervention is a five-session intervention developed to build communication skills, improve social support, and improve stress management. It is easy to learn and does not require a healthcare professional or mental health specialist to deliver. For this study, the investigators plan to deliver to individuals during inpatient visits, in-person appointments or via telemedicine (phone or videoconference), as appropriate or per participant preference. The first four sessions are approximately 60 minutes in length.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: During the first four post-cesarean days, the investigators will administer subcutaneous ketamine (0.5 mg/kg) and a repeated dose of 0.5 or 0.7 mg/kg \~24 hours later (the second dose will be increased to 0.7 mg/kg if no severe adverse effects are reported after the first dose and the patient is in agreement with the dose escalation).
Study: NCT05354739

Intervention type: DEVICE
Intervention: The vibration cold device (BUZZY)
Description: If the patient fulfils the inclusions criteria, the research nurse will obtain informed consent from a parent or legal guardian and assent form if the child is 7years or older. She will assess the ability of the child to use the Faces Pain Scale-Revised (FPS-R), as a pain assessment instrument used by the child. It is a six cartoon faces showing a normal facial expression if no pain, progressing into the facial expression with very severe pain. FPS-R is graded from zero to ten; the child will be asked to quantify the pain by: no hurt, hurt, or very much hurt. This scale is widely used not only in research but also in a routine bases in ours and other units by the nursing staff and are familiar with it. The research nurse is one of the nurses used the same scale during the routine work and will be trained further to ensure consistency, she will document the findings prior, during and after the procedure. This instrument was reliable, valid, and standardized

Intervention type: DEVICE
Intervention: The vibration cold device (BUZZY)
Description: If the patient fulfils the inclusions criteria, the research nurse will obtain informed consent from a parent or legal guardian and assent form if the child is 7years or older. She will assess the ability of the child to use the Faces Pain Scale-Revised (FPS-R), as a pain assessment instrument used by the child. It is a six cartoon faces showing a normal facial expression if no pain, progressing into the facial expression with very severe pain. FPS-R is graded from zero to ten; the child will be asked to quantify the pain by: no hurt, hurt, or very much hurt. This scale is widely used not only in research but also in a routine bases in ours and other units by the nursing staff and are familiar with it. The research nurse is one of the nurses used the same scale during the routine work and will be trained further to ensure consistency, she will document the findings prior, during and after the procedure. This instrument was reliable, valid, and standardized
Study: NCT05416788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical manipulation
Description: high-velocity, low-amplitude cervical manipulation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: lateral flexion and cervical rotation without manipulation
Study: NCT06172335

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cetoleic acid
Description: Very long monounsaturated fatty acid (C22:1n-11)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control oil
Description: Mix of oils with low cetoleic acid content
Study: NCT05995886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wiidookaage'win Facebook Group
Description: An online social media group program that incorporates social support, mindfulness-based, and cultural practices that may support OUD recovery.
Study: NCT04931849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: Avatrombopag is a small molecule thrombopoeitic receptor agonist (TPO-RA) that mimics the biological effects of thrombopoeitin (TPO)
Study: NCT06091540

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feasibility and Efficacy of Individual SH+ Intervention
Description: The key parameter of interest will be the extent of psychological distress encountered by the participants. In addition, various secondary outcomes will also be evaluated, encompassing depression, anxiety, post-traumatic stress disorder (PTSD) symptoms, psychosocial well-being, and grief levels. The evaluation of the intervention's effectiveness on the sample of interest will hinge on the comparison of scores obtained during the pretest and posttest measurement phases.
Study: NCT05128760

Intervention type: DIAGNOSTIC_TEST
Intervention: characterization of aPL
Description: characterization of aPL profile, GT profile and leukocytes activations markers (NETs, TREM-1)

Intervention type: DIAGNOSTIC_TEST
Intervention: characterization of aPL
Description: characterization of aPL profile, GT profile and leukocytes activations markers (NETs, TREM-1)

Intervention type: DIAGNOSTIC_TEST
Intervention: characterization of aPL
Description: characterization of aPL profile, GT profile and leukocytes activations markers (NETs, TREM-1)

Intervention type: DIAGNOSTIC_TEST
Intervention: characterization of aPL
Description: characterization of aPL profile, GT profile and leukocytes activations markers (NETs, TREM-1)

Intervention type: DIAGNOSTIC_TEST
Intervention: characterization of aPL
Description: characterization of aPL profile, GT profile and leukocytes activations markers (NETs, TREM-1)
Study: NCT05437315

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bi-4SCAR GD2/PSMA T cells
Description: Infusion of bi-4SCAR GD2/PSMA T cells at 10\^6 cells/kg body weight via IV
Study: NCT06574438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIFIGA program
Description: receives the Artificial Intelligence Family Involvement Generative Agent (AIFIGA) program and uses it for 3 months
Study: NCT04778085

Intervention type: BEHAVIORAL
Intervention: Illness management and recovery
Description: Treatment given in groups, weekly for 10-12 months.

Intervention type: OTHER
Intervention: Semi-structured interviews
Description: Semi-structured individual or group interviews conducted three times with staff on each participating outpatient clinic.
Study: NCT05440201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amount of anticoagulant Clexane
Description: Change (increase/decrease) the amount of Clexane administered at the dialysis start.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amount of anticoagulant Clexane
Description: Change (increase/decrease) the amount of Clexane administered at the dialysis start.
Study: NCT05416320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol
Description: Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Subject's already prescribed drug
Description: Subjects will continue to use their already prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months.